Chimeric VLP vaccines to Prevent HTLV-1 Infection
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for Chimeric VLP Vaccines to Prevent HTLV-1 Infection.
T Cell Receptors Targeting HPV 6 or HPV 11
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens.
Electrochemical Impedance Spectroscopy (EIS) for Non-Destructive Assessment of Epithelial Integrity
This technology includes a novel apparatus and method that utilizes Electrochemical Impedance Spectroscopy (EIS) to assess the integrity of epithelial cell membranes non-destructively. By applying frequency-modulated voltage signals and facilitating fluid exchange on both sides of the epithelial tissue, this technology allows researchers to characterize membrane-specific responses with unprecedented accuracy.
Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus
The vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that will likely change the HCV treatment paradigm. However, the effectiveness of these new drugs can vary depending on the HCV genotype. Thus, there is still the need for additional new therapeutics against HCV.
C8166-45 and C8166 Cells
Summary:
The National Cancer Institute (NCI) seeks licensees for human T-cell lines, C8166 and C8166-45, transformed by HTLV-1. C8166-45, a subclone of C8166, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth.
Clinical Advancements in Intracellular Pathogen Infection Treatment through CD47 Blockade for Augmented Phagocytic Clearance
The technology described involves a groundbreaking method for treating intracellular pathogen infections by targeting CD47, a widely expressed transmembrane glycoprotein that acts as a ligand for phagocytic receptors. By administering agents that inhibit CD47 binding to these receptors, the approach enhances the phagocytic removal of infected cells, leading to increased clearance of intracellular pathogens.
Advancements in Coronavirus Vaccine Development: Innovative Engineered RBD Antigens Redefining the Landscape
Novel Engineered RBD Antigens: Elevating Coronavirus Vaccine Efficiency and Efficacy. These groundbreaking antigens, derived from the spike protein's receptor-binding domain, are meticulously designed through a computational pipeline, resulting in superior attributes. They increase protein yield sevenfold, ensuring efficient large-scale manufacturing. With elevated thermal stability and a tenfold boost in antibody production, these antigens present a significant stride towards potent and globally accessible coronavirus vaccines.
Advancing Anthrax Detection with Monoclonal Antibodies Against Bacillus anthracis Protective Antigen
This technology involves the creation of monoclonal antibodies through hybridoma technology, specifically, hybridomas 3B6, 14B7, 2D3, 2G4, 1G3, 6H3, 6C5, and 3D12, which exhibit a high degree of reactivity with Bacillus anthracis protective antigen (PA). These monoclonal antibodies have shown great promise in the field of anthrax detection and diagnosis. Their exceptional specificity for Bacillus anthracis PA suggests their potential application in diagnostic devices.
Monoclonal Antibodies in the Advancement of Bacillus anthracis Diagnosis and Surveillance
Monoclonal antibodies produced by hybridomas IE5, IE9, and 13B3 are specific for the Bacillus anthracis PA20 fragment. These antibodies hold significant potential for rapid and precise Bacillus anthracis diagnosis in clinical and environmental samples. They can be employed in various diagnostic assays, offering a valuable tool for public health and biosecurity applications. Rigorous testing and validation are essential before their integration into diagnostic devices.
Advancements in HIV-1 Treatment with Broadly Neutralizing Monoclonal Antibodies N6 and VRC07-523LS
The Vaccine Research Center has engineered two monoclonal antibodies, N6 and VRC07-523LS, as new contenders in the fight against HIV-1. These antibodies are designed to target the virus more effectively by removing certain glycans and modifying amino acids to enhance their neutralizing capability and reduce the risk of autoimmunity. The technology holds promise for improved HIV-1 treatments and may offer broader protection due to its potential coverage of various viral variants.